Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Question
Sorry, no.
I know who I'm betting on.
Oh no I can barely sit still.
Here are the links:
http://www.google.com/patents/WO2003022252A2?cl=en
https://www.google.ch/patents/US9078827
The reason he did not supply the links is because neither one has anything to do with nPODDDs or Rexista, which even basic skimming of the text by a NON-LAWYER would make obvious.
The first is for sustained-release formulations and has zero to do with abuse-deterrence. The second regards the use of clays (bentonite) to prevent alcohol dose-dumping, which is not utilized in Rexista. Both are for CAPSULES, not tablets, and neither has anything to do with nPODDDs or Rexista.
So anybody still claiming that nPODDDs is unique or patented, I'm still waiting for those claims to be posted. Total failure so far.
Wrongest Wrong In Wrongtown:
It's very easy, Samsa.
Completely totally retarded.
That's just stooopid.
Wrong, as usual.
Not sure what you mean.
Not a total loss.
You are mistaken, wimuskyfisherman
It would be funny if not so true.
Roxybond's HAL studies are awful.
Easily extracted (IV abuse) and well-liked when snorted. If this drug gets approved with an ADF label there should be a Congressional inquiry into who got paid off and how much they got. Oxaydo's HAL studies look better than this POS.
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm550016.htm
FDA Briefing Information for the April 5, 2017 Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF - 5.8MB)
Page 99:
Not how it works.
Sounds about right, Dr. PeteRose
Methadone.
Don't need to, already have.
FDA's Sharon Hertz must be very concerned.
Bullshit.
Looks like bad news to me.
http://www.cnn.com/2017/03/29/health/christie-opioid-trump-appointment/
For clarification.
Purdue vs. Elite
It's been a while since I read up on this, but here is what I remember:
1. Important: King sued Purdue first, then Purdue counter-sued.
2. Equally important: There was no judgement (or even trial) in King vs Purdue. It was settled a few weeks before jury trial.
3. In pretrial arguments, King argued Purdue's patents describe coated antagonist interspersed within a "matrix" that includes agonist, and Embeda does not infringe the patents because it has an inner layer of antagonist which is separated from an outer layer of agonist. Purdue argued that as long as everything is in the same capsule then it's all theirs.
4. Elite's patents barely mention the agonist and only describe the antagonist bead. Elite's patents clearly describe a single entity antagonist bead, while Purdue's patents clearly describe coated antagonist interspersed within a matrix that contains agonist.
I do not think it is certain Purdue will sue Elite over SequestOx or generic Embeda, but it is very possible. They have bigger fish to fry trying to protect their OxyContin franchise, and they are being sued by half the cities and states in the U.S. The outcome of a trial could go either way, depending on the interpretation of #4 above. Frequently, due to their technical nature, pharma patent cases are argued in front of a judge and not a jury, but Elite would probably demand a jury trial and would drag Purdue through the mud. Purdue's history and contribution to drug abuse in the U.S. is despicable, and likely they would get zero sympathy from a jury in their effort to prevent lower-cost generic ADF's.
On the other hand, in regards to a generic OxyContin ANDA, it is very likely Purdue would sue Elite. They've said as much multiple times. OxyContin has more than a dozen patents listed in the Orange Book. The Supreme Court decision in November 2016 was only over 4 of those patents. They will continue to sue everybody who files a generic OxyContin ANDA until they're out of patents.